nontaxane microtubule dynamics inhibitor

Eribulin      

pathologytreatmentpatient Demonstrated benefit and harm k      
advanced breast cancer (metastatic)eribulinnot classified

versus

eribulin superior to treatment of physician in terms of overall survival in EMBRACE (Cortes), 2011

3 trialsmeta-analysis